GoMeyra, an innovative cloud software company dedicated to providing enterprise technological solutions for medical laboratories, has launched a next generation healthcare management platform, GoMeyra MD, a suite of modules giving medical professionals the software needed for comprehensively managing patient care and electronic healthcare records, including a proprietary telehealth application. The first module available is the […]
ExThera Medical, maker of the only effective pathogen-removal, hemoperfusion filter approved for patient use in Europe, and Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, have expanded distribution of ExThera’s Seraph 100 Microbind Affinity Blood Filter in Turkey, Finland, and Estonia. Earlier this year ExThera Medical and […]
https://interhospi.com/wp-content/uploads/sites/3/2021/09/ExThera.png10681086panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 13:39:362021-09-21 13:39:36ExThera expands European distribution of Seraph 100 filter for blood purification and pathogen reduction
DYSIS Medical has launched DYSIS View, a compact and portable colposcope, which includes the company’s innovative computeraided cervical mapping technology that helps healthcare professionals detect cervical lesions more clearly.
The University Hospital Salzburg, part of the Salzburg State Hospitals (SALK), is the world’s first hospital to implement Medical Microinstruments’s Symani Surgical System for commercial use in its robotic microsurgery programs. As one of the largest hospitals in Austria, SALK will specifically use Symani to further enhance its capabilities in oral and maxillofacial surgery.
https://interhospi.com/wp-content/uploads/sites/3/2021/09/Symani-scaled.jpg19512560panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-21 13:28:162021-09-21 13:30:50Medical Microinstruments sees first commercial installation of Symani Surgical System
Recent tragic events in India and Iraq have focused minds on the safety measures in place at hospitals for the storage of oxygen supplies. Now gas processing systems specialist Oxair is urging medical and healthcare facilities across the world to avoid shortcuts and consider safety above all when ordering in their oxygen supplies.
At least 22 people died in a hospital in India when the flow of oxygen through ventilators was fatally interrupted. Meanwhile in Iraq 174 were killed in two separate catastrophic fires within three months at hospitals in the capital Baghdad and Nassiriya, reportedly caused by oxygen tanks exploding.
International health agencies had sounded warnings about a growing crisis of severe oxygen shortages, which is leading to hospitals outsourcing as many oxygen cylinders as possible. However, there are potential pitfalls such as a lack of suitable and safe storage space. Oxair has developed a simpler, safer solution – and it has already been deployed and proven.
Oxygen Pressure Swing Adsorption system
A significant number of hospitals across India and other regions of the Middle East and Australasia are now self-sufficient and saving lives with an off-the-shelf Oxygen Pressure Swing Adsorption (PSA) system. These are high quality, robust medical devices designed to last and deliver consistent, high purity oxygen on tap to hospitals and healthcare facilities – even in the remotest locations around the world.
As it extracts its supplies directly from the atmosphere, PSA Oxygen offers better patient care with a permanent flow of high-quality oxygen. This system saves room space, offers output pressure and a flow rate to suit the needs of the hospital and is capable of piping oxygen to every department where it is needed.
Oxair’s system delivers constant oxygen of 94-95 per cent purity through PSA filtration, a unique process that separates oxygen from compressed air. The gas is then conditioned and filtered before being stored in a buffer tank to be used directly by the end user on demand. Orders for ready-to-use, standalone Oxygen PSA units can be turned around in just a few weeks, depending on local lockdown conditions.
David Cheeseman of Oxair said: “We’ve seen terrible consequences recently from a lack of life-saving medical oxygen, especially when treating Covid-19 patients. But there’s a lot more to it than simply pulling in extra cylinder supplies. If exposed to certain conditions the storage, handling and removal of these cylinders can also be hugely dangerous. It’s precisely the type of far-lying medical facility that might run out of oxygen, that is least equipped to store more of it safely and securely.
“We believe our PSA systems are the safest and ultimately cheapest solution for hospitals anywhere. The design of these PSA systems as ‘plug-and-play’ means that they are literally ready to start working as soon as they are delivered and plugged in, with voltage adapted to the country of delivery. So, hospitals can rely on technology that is tried and tested over many years, coupled with almost instant access to vital oxygen supplies under significantly safer conditions.”
For further information on Oxair’s products and services visit: www.oxair.com.au
https://interhospi.com/wp-content/uploads/sites/3/2021/09/oxair_2.jpg492520panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-09-09 07:03:202021-09-09 07:03:20Oxygen: Tragic incidents highlight safety dilemma for hospitals
Needlestick injuries are one of the most frequent accidents in hospitals and they can be particularly dangerous for healthworkers if there are contaminants involved, such as HBV, HCV or HIV.
Greiner Bio-One has released the VACUETTE EVOPROTECT safety blood collection set in an effort to prevent needlestick injuries during blood collection. The semi-automatic click mechanism protects the user from the risk of needlestick injuries and makes the daily task of blood collection easier. The safety triggers located on the side of the device facilitate one-handed activation. The needle is then automatically retracted and, at the same time, safely and irreversibly enclosed in the safety shield. A clearly audible click confirms that the safety mechanism is successfully activated.
The safety blood collection set meets current safety requirements and provides substantial support for safe blood collection and infusion with the same set.
Swiss aircraft manufacturer Pilatus, with its development partner Aerolite AG, now offers integration of the EpiShuttle in their medevac PC-24 aircraft.
The global COVID-19 pandemic situation has fuelled a growing demand for air transport solutions for infectious patients. To prevent in-flight transmission of viruses to cockpit and cabin crew, infected individuals are transported in an isolation unit known as an EpiShuttle. With its large cargo door and complete air ambulance equipment, the PC-24 is ideally suited for these missions.
EpiShuttle
Using an adapter, the EpiShuttle is attached to a universal transport trolley allowing transfer movements on the ground and positioning in the cabin. Loading is performed with the unique loading device, which automatically transfers the EpiShuttle unit plus patient into the cabin. The completely flat cabin floor and rollers on the transport trolley ensure the unit can be freely pushed into the desired position, where it is then secured directly to the seat rails using retaining devices.
“We are glad to see that Pilatus offers the very best patient comfort and safety. With the EpiShuttle’s features of reclinable backrest, transparent hard-top and excellent patient access, their passengers, both patient and staff, will have a safer and better ride. We are also impressed by Aerolite’s ingenuity when integrating the EpiShuttle into the medevac PC-24, an excellent aircraft for the transfer of infected patients with the EpiShuttle,” says Ellen Cathrine Andersen, CEO in EpiGuard.
Patient monitoring is ensured by medical equipment placed on a cradle right next to the EpiShuttle and powered by the on-board power supply. As with regular patient transport operations, medical personnel occupy cabin seats in the immediate vicinity of the EpiShuttle, and can attend to the patient at any time.
Modular isolation system
In 2015, during an outbreak of Ebola in Africa, Norway’s EpiGuard developed a modular isolation system which is now also in use for Covid-19 missions. The EpiShuttle features a modular reusable design and eight medical airlocks to ensure safe patient handling.
EpiGuard, a Norwegian company established in 2015, provides solutions for safe transportation of contagious patients. Their team of medical experts and engineers developed the EpiShuttle based on analysis and clinical first-hand experience from previous global epidemics. The EpiShuttle is NATOs stock listed and CE-marked as a class one medical device.
https://interhospi.com/wp-content/uploads/sites/3/2021/08/pilatus_1_web.jpg11341701panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-08-13 09:38:372021-08-13 09:38:37Pilatus now offers medevac PC-24 aircraft with the EpiShuttle
Philips showcased the Philips Patient Flow Capacity Suite and Philips Acute Care Telehealth at HIMSS21 in Las Vegas this week. These two new HealthSuite solutions allow health systems to integrate informatics applications that can be combined and scaled according to need. They are secure, cloud-based and intended to break down barriers across patient care in a cost-effective model. The solutions, Philips says, help health systems deliver on the aim of a connected, protected, future-ready and cost-predictive single-cloud infrastructure and Software-as-a-Service (SaaS) model.
Patient Flow Capacity Suite: A patient logistics solution that helps manage the patient journey across the entire care continuum. By taking a holistic approach to care coordination and combining clinical and operational data, the solution helps to provide the visualization and machine learning supported analytics that can enable more informed patient flow decisions. Care is orchestrated in a structured manner across the entire healthcare network, including affiliate networks as well as post-acute settings. Patient Flow Capacity Suite connects the front lines with hospital enterprise operations to systematically predict demand, make patient transition decisions, and spot patient flow bottlenecks.
Acute Care Telehealth: Building on Philips’ decades-long expertise in Tele-ICU solutions, Acute Care Telehealth provides a configurable and flexible solution to help health systems realize their virtual care and wider enterprise telehealth ambitions. The solution’s scalability allows health systems to deploy Acute Care Telehealth in a centralized command centre, or a decentralized model of telehealth dependent on their needs. By allowing customers to add additional hospitals, clinical units or beds, Acute Care Telehealth grows as each organization’s telehealth strategy evolves.
Additional clinical and operational solutions will be added to Philips HealthSuite. Next, updates are planned for Philips Electronic Medical Record and Philips Acute Care and Anesthesia Workspace.
Driving connected, future-ready care
As care settings expand beyond the hospital, health systems are seeking new ways to manage the influx of data while addressing challenges with IT resources and budgets. The adoption of platform-based IT models is on the rise, with more than 30% of global economic activity expected to be mediated by digital platforms in six years, yet experts estimate only 3% of companies have adopted an effective platform strategy [1].
Philips HealthSuite securely stores critical healthcare data and provides both advanced analytics and AI capabilities, while delivering industry-leading interoperability to help enable precision care and provide care anywhere. With these new HealthSuite solutions, health systems can liberate data from silos and connect it in a way that enables care teams to turn data into actionable insights and collaborate to better serve patients.
“Health systems today must continue to evolve to meet the needs of patients and providers, ensuring care is connected across settings and that care can be delivered anywhere – all of which requires agile and secure platforms that will allow them to innovate and scale as demands shift,” said Roy Jakobs, Chief Business Leader, Connected Care, Philips. “Our cloud-based HealthSuite solutions are a milestone in how they support the acceleration of digital transformation in health systems to deliver better, patient-centric care, while reducing costs and resources.”
Modular approach
Using a modular approach, Philips offers flexible solutions and services to solve specific customer needs, making solutions easy to implement, install, maintain, and use. All solutions benefit from the same SaaS model, which can help to lower initial deployment costs and relieve ongoing IT resource strains.
Digital transition
Philips’ informatics solutions are an integral part of Philips Care Collaboration (currently available only in North America), a collaborative approach to supporting a healthcare organization’s digital transformation. As health systems seek to manage, coordinate, orchestrate and synchronize care across the health continuum, each organization’s digital journey will be unique. Through Care Collaboration, Philips acts as a partner to healthcare organizations to gain a deep understanding of their challenges and determine how Philips’ advanced HealthSuite solutions can help them support data and workflows to deliver enhanced patient care.
https://interhospi.com/wp-content/uploads/sites/3/2021/08/Philips_care-collab-center_web.jpg10561920panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-08-13 09:18:302021-08-13 09:39:53Philips introduces new HealthSuite solutions to support digital transformation
UV Smart aims to provide healthcare facilities all over the world with validated UV-C disinfection methods to ensure a safer environment for patients and healthcare professionals.
https://interhospi.com/wp-content/uploads/sites/3/2021/07/UvSmart-108-1-scaled.jpg144025603wmediahttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png3wmedia2021-07-23 08:32:482021-08-11 07:39:07UV Smart aims to provide healthcare facilities with UV-C disinfection
Endologix, a California-based, global medical device company focussed on the treatment of vascular disease, says the company’s ChEVAS (Chimney EndoVascular Aneurysm Sealing) System has been granted a Breakthrough Device Designation from the US FDA. The ChEVAS System is an investigational endovascular abdominal aortic aneurysm (AAA) sealing therapy designed to combine the Nellix 3.5 endograft with parallel visceral stents to enable treatment of patients with juxtarenal, pararenal and suprarenal AAA.
The FDA Breakthrough Devices Program gives patients more timely access to medical devices that may provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Breakthrough Devices receive priority review by FDA, and the program provides opportunities for early interaction with FDA personnel to expedite the review and approval process.
ChEVAS is currently being evaluated through the ChEVAS ONE IDE (Investigational Device Exemption) clinical study that is approved to enrol approximately 120 patients at up to 50 clinical sites worldwide. The national principal investigators of the ChEVAS ONE study are Francis Caputo, MD (Cleveland Clinic Foundation); William Jordan, MD (Emory University School of Medicine); Joseph Lombardi, MD (Cooper University Health Care) and William Quinones-Baldrich, MD (UCLA).
“The aneurysm sac sealing technology featured in the ChEVAS system is designed to reduce endoleaks, including gutter endoleaks, that are reported after endovascular treatment of complex aneurysms,” explained James McKinsey, MD, the leading enroller in the ChEVAS ONE IDE study. “Our initial clinical results of this therapy have been promising in a challenging group of patients.”
Dr. McKinsey will present his initial experience with ChEVAS at the Eastern Vascular Society Annual Meeting on September 26.
Matt Thompson, MD, chief medical officer at Endologix, said: “The ChEVAS System represents an important therapy that provides an ‘off-the shelf’ treatment to an underserved patient population who have complex abdominal aortic aneurysms. We are delighted that the FDA has designated ChEVAS as a Breakthrough Device, as this will facilitate our ability to develop this technology and make it available to patients in an expedited fashion. The ChEVAS System joins the PQ Bypass DETOUR System as the two FDA-designated Breakthrough Devices in our clinical investigational programs, which is reflective of our aspiration to provide innovative and disruptive technologies to address clinically relevant therapeutic gaps.”
https://interhospi.com/wp-content/uploads/sites/3/2021/07/Endologix_ChEVAS_Illustration.jpg768520panglobalhttps://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.pngpanglobal2021-07-22 08:52:112021-07-22 08:52:11Endologix receives FDA Breakthrough Device Designation for ChEVAS system for sealing endovascular aneurysm
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
